论文部分内容阅读
膀胱癌发病率逐年增高且易复发,如能早期诊断,早期治疗,患者生存状况将会明显改善。目前用于临床膀胱癌检测的肿瘤标记物的研究主要集中在NMP22、Survivin、HA-HAase、BTA,UBC、TLMA、CD44V6、L-selectin、MCM5、p27、MSI、FB/FDP、VEGF、BGA、integrin、centrosome等。对于不同发展阶段或不同类型的膀胱癌,单一肿瘤标志物检测的灵敏度有不同程度的差异。它们最有价值的潜在作用是监测膀胱癌复发和筛查有膀胱刺激征和血尿的患者,并且几种肿瘤标志物的合理联合应用将成为诊断膀胱癌的有效工具。
The incidence of bladder cancer increased year by year and easy to relapse, such as early diagnosis and early treatment, the patient’s survival will be significantly improved. At present, most of the tumor markers used in clinical bladder cancer detection are mainly concentrated on NMP22, Survivin, HA-HAase, BTA, UBC, TLMA, CD44V6, L-selectin, MCM5, p27, MSI, FB / FDP, integrin, centrosome and others. For different stages of development or different types of bladder cancer, the detection sensitivity of a single tumor markers have varying degrees of difference. The most valuable of their potential role is to monitor the recurrence of bladder cancer and screening patients with bladder irritation and hematuria, and a reasonable combination of several tumor markers will be an effective tool to diagnose bladder cancer.